OSE Immunotherapeutics S.A.
OSE.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.01 | -0.00 | 0.13 |
| FCF Yield | -15.92% | -11.75% | 49.86% | -9.10% |
| EV / EBITDA | -8.51 | -9.50 | 1.68 | -9.88 |
| Quality | ||||
| ROIC | -21.46% | -16.50% | 33.95% | -14.25% |
| Gross Margin | 0.00% | 103.73% | 83.62% | 100.00% |
| Cash Conversion Ratio | 1.19 | 0.92 | 1.17 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 42.85% | 33.03% | 34.66% | -25.88% |
| Free Cash Flow Growth | 1.43% | -127.40% | 927.21% | 31.33% |
| Safety | ||||
| Net Debt / EBITDA | -0.89 | -1.51 | -0.53 | -2.32 |
| Interest Coverage | -13.82 | -13.63 | 24.73 | -9.66 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 794.29 | 80.25 | 8.23 | 186.94 |